accesso Technology Group Reports Strong 2025 Results and Launches £14.5 Million Tender Offer
accesso posts 2025 revenue of ~$155m, cash margins near 15%, and launches a £14.5m tender offer at £3.00 per share, signalling confidence and robust cash generation.
This article covers information on Accesso Technology Group PLC.
LON:ACSOaccesso’s 2025 trading: revenue ahead, margins holding, cash strong
accesso Technology Group has posted a solid update for 2025, with revenue slightly ahead of market expectations at approximately $155 million and cash EBITDA margins approaching 15%. Despite softer transaction volumes in the key summer months, higher service revenues helped balance the mix and keep profitability steady.
Cash generation remains a bright spot. Net cash at 31 December 2025 was $30 million, underlining a robust balance sheet after an active buyback programme.
Key numbers from the update
| 2025 revenue | Approximately $155 million (slightly ahead of market expectations) |
| Cash EBITDA margin | Approaching 15% |
| Cash EBITDA | In line with prior year (exact figure not disclosed) |
| Net cash (31 Dec 2025) | $30 million |
| 2025 to early 2026 buyback | Completed – approximately 7% of issued share capital |
| New tender offer | Up to £14.5 million at an expected price of £3.00 per share |
| Indicative shares via tender | Up to approximately 4.8 million shares |
| 2026 outlook | Expected to be in line with current market expectations |
Why the revenue mix shift matters for accesso
Transaction volumes softened in summer, the most important period for many of accesso’s leisure and attractions customers. That would typically pressure revenue tied to per-ticket or per-transaction activity.
However, accesso offset the dip with higher service revenues, which are usually more predictable and less seasonal. Alongside “disciplined cost management”, that helped keep cash EBITDA in line with last year and margins close to 15%. In plain terms: the model is showing resilience even when the turnstiles slow.
£14.5 million tender offer at £3.00: what it means and why it matters
After completing a repurchase equal to roughly 7% of its issued share capital through 2025 and early 2026, the Board plans a tender offer for up to £14.5 million of shares at an expected price of £3.00 per share. A tender offer is a time-limited invitation for shareholders to sell some or all of their shares back to the company at a fixed price.
- Signal: management is confident in the balance sheet and cash generation.
- Maths: at £3.00 per share, the tender could buy back up to approximately 4.8 million shares.
- Impact: if fully taken up, the share count falls, which can boost per-share metrics. The exact percentage impact on the share base is not disclosed.
- Process: detailed terms, timetable and resolutions will follow in due course.
My take: pairing a completed buyback with a fresh tender is a strong capital returns message. It suggests the Board sees value in the shares at these levels and has headroom to act without crimping investment.
Major customer updates shaping 2026
Two big customer points stand out. First, service for a major customer is continuing into 2026 and the parties are close to finalising updated commercial arrangements, with documents expected shortly. That continuity matters for revenue visibility.
Second, another major customer will not renew its agreement for the same software solution beyond 31 January 2026, as previously anticipated. The non-renewal was flagged earlier, so it should be in expectations, but it is still a headwind to manage.
The strategy response: focus and cost alignment
Management highlights “decisive and timely” actions to align the cost base with market conditions and long-term priorities. Combined with the strategic refocus through 2025, these steps are expected to “materially support Cash EBITDA performance” in 2026.
Translation: even with customer churn and a tougher 2025 revenue environment, the business expects to protect profitability while pursuing targeted growth investments.
Outlook: steady guidance with execution milestones ahead
The Group currently expects its 2026 outturn to be in line with current market expectations. No numerical guidance is provided. The tone is one of controlled execution: solid balance sheet, cash-generative operations, and a pragmatic reshaping of costs to support margins.
Positives I see:
- Revenue ahead of expectations in 2025 despite summer softness.
- Margins approaching 15% and cash EBITDA in line with last year – evidence of operational discipline.
- $30 million net cash after meaningful buybacks – financial flexibility intact.
- Tender offer adds a second leg to capital returns.
Watch-outs:
- Non-renewal of a major customer from 31 January 2026 – requires backfill and mix management.
- Reliance on service revenue to offset transactional dips – needs continued execution to hold margins.
- Final terms of the updated major customer contract – documentation is “expected shortly” but not yet signed.
Jargon buster: two lines you might care about
- Cash EBITDA: a profitability metric similar to EBITDA that focuses on cash-based performance and excludes non-cash items. It is used here as a gauge of operating efficiency and cash-generating capacity.
- Tender offer: a company invites shareholders to sell shares back at a set price for a limited period. If demand exceeds the offer size, acceptances are usually scaled back.
What to watch next from accesso
- Tender offer circular: timetable, mechanics and any scale-back rules.
- Signed documentation for the updated commercial arrangements with the major customer.
- Full year results in April 2026: detail on service vs transactional revenue mix, churn impact and cash conversion.
Josh’s bottom line
This is a reassuring update from accesso. Revenue edged past expectations, margins held up, and the cash balance stayed healthy. The planned £14.5 million tender at £3.00 per share underlines confidence and provides a clear route to enhance per-share value.
The flip side is customer concentration risk. One large non-renewal from 31 January 2026 will need offsetting, and investors should look for confirmation of the new terms with the other major customer. For now, guidance is steady, execution looks disciplined, and the balance sheet is doing the heavy lifting. Sensible, shareholder-friendly, and focused – with a few near-term milestones to clear.
Related
Keep reading
Investing
AstraZeneca’s Enhertu delivers Phase III lung cancer PFS win
Enhertu delayed disease progression versus standard care in a Phase III lung cancer trial, supporting its potential move into first-line treatment.
JoshuaAugust 17, 2026
Investing
Optima Health FY26 results: growth beats expectations as PAM integration begins
Optima Health beat adjusted EBITDA expectations in FY26, while the £100 million PAM acquisition reshaped its growth prospects and balance sheet.
JoshuaAugust 17, 2026
Investing
Nostrum Oil & Gas Agrees $304.6 Million Kazakhstan Sale Ahead of Wind-Down
Nostrum plans to sell its Kazakhstan operations, repay secured notes in full and begin an orderly wind-down after completion.
JoshuaAugust 17, 2026
Last updated
Category
InvestingLikes
Star Rating
No ratings yet
Comments
No comments yet - start the conversation.